Tissue factor pathway inhibitor, a natural anticoagulant in the extrinsic pathway of blood coagulation, is associated with the endothelial membrane and presumed to be released by heparin.
Introduction
plasma, in platelets and on the endothelial cell surface.
Tissue factor pathway inhibitor has been detected in hu-^ P athwa y of tissue factor P athwa y id^tiuot 5^* -man plasma, where it is associated with, and regulated sis ' its Presentation on the cellular surface and its associby, low density lipoprotein. It functions as a potent natuation with ^'Proteins remains unclear (9) . It has been ral anticoagulant that regulates tissue factor-mediated su gS ested that domain 3 is involve d in the binding to coagulation inhibition in the extrinsic pathway (1 -3). me cdl membrane > Hpoproteins, or in tissue factor pathThe native inhibitor consists of three Ointe-type inhibiwa ? inhibitor-degradation via low density lipoprotein retor domains (1) , connective chains and a negatively ceptor-related protein on hepatocytes (10) . charged N-terminus, the total relative molecular mass Injection of heparin has been found to result in a rapid being approximately M r 36000 to M r 42000. The tissue dose-dependent 2-10 fold increase of tissue factor pathfactor pathway inhibitor gene has been localized on way inhibitor concentration in plasma (11, 12) . The enchromosome 2 and the primary structure contains 276 dothelium bound tissue factor pathway inhibitor beamino acids including an acidic N-terminus, the three comes evident after injection of heparin in amounts Kunitz-type inhibitory domains and a basic carboxy ter-equivalent to 50-90% of the total intravascular pool minal end (4, 5) . Kunitz-domsiM 51 has been identified (13) . Moreover, heparin effects the release of tissue as the site of binding factor Vila/tissue factor complex, factor pathway inhibitor into endothelial cell culture suwhile domain 52 binds activated factor X (FXa). Tissue pernatant when added to the medium (14) . The increased factor pathway inhibitor is mainly synthesized by vascu-tissue factor pathway inhibitor activity suggested that lar endothelium, where it is bound to heparan sulphate this inhibitor is involved in the post-heparin anticoaguor glycosaminoglycans (6,7), and by other cells, e. g. lant effect following heparin administration. A heparin megakaryocytes and chondrocytes (8) . There are three binding site C-terminal from domain 53 has been posintravascular pools of tissue factor pathway inhibitor, in tulated as a mediator of heparin-induced tissue factor pathway inhibitor release from the cell surface (15) . However, it is also presumed that tissue factor pathway inhibitor is released from intracellular stores (16) . So far, no results have been reported that show the proteinturnover of membrane bound tissue factor pathway inhibitor.
We have already determined the influence of cyclosporine on the vascular endothelium in heart transplant patients, resulting in an increased tissue factor pathway inhibitor plasma concentration (17, 18) . These results were described as cytotoxic or modulatory effects on the endothelial cells (19) .
In the present study we describe the flow cytometric detection of tissue factor pathway inhibitor on endothelial cells using three monospecific tissue factor pathway inhibitor-antisera which recognize the reactive site of Kunitz-type domain 51 and 52 as well as the corresponding region of domain 53. We investigated the influence of heparin on the release of membrane-bound tissue factor pathway inhibitor from endothelial cells by flow cytometry, and we suggest a potential mechanism for tissue factor pathway inhibitor release from the vascular endothelium.
Materials and Methods
All chemicals were purchased from the Sigma (Deisenhofen, Germany) unless otherwise stated. 204 and the immunisation of rabbits were performed using standard techniques by QCB Inc. (Hopkinton, MA). For further use the antisera were heated for 30 min at 56 °C and the IgG fraction was separated by (NH4)2SO4 fractionation at 35% saturation followed by Protein A affinity chromatography to remove residual proteins. The IgG was then dialysed against HaO. Aliquots were then stored at -20 °C until further use. As negative control non-immune rabbit IgG was prepared from preimmunserum by (NILOaSCU precipitation followed by dialysis as described above. Protein A absorption was omitted.
Synthesis of polyclonal rabbit antisera

Determination of cross-reactivities
All antisera were tested against each oligopeptide for specificity and to exclude cross-reactivity. The antigens were immobilized on an Immobilon AV® membrane (Millipore, Eschborn, Germany) and incubated with each antiserum after 20 min blocking with 20 g/1 casein. The detection was performed by standard methods using anti-rabbit horse radish peroxidase 
Flow cytometry
For flow cytometric analysis the cells were grown until 80% confluence, then removed in 0.5 g/1 trypsin and 0.2 g/1 ethylenediaminetetraacetic acid. The cells were washed twice in Dulbecco's phosphate-buffered saline containing 10 g/1 foetal calf serum and resuspended at 10 6 cells per 100 μΐ. Each polyclonal IgG fraction was added in a final dilution of 1:100 from the stock solution. After Ih incubation at room temperature and additional washing, the secondary polyclonal goat anti-rabbit fluorescein labelled antibody F(ab')2-fragment (Dianova, Hamburg, Germany) was added in a final dilution of 1:200. After Ih incubation at room temperature the cells were washed twice in Dulbecco's phosphate-buffered saline containing 10 g/1 foetal calf serum and resuspended in 500 μΐ Dulbecco's phosphate-buffered saline containing 10 g/1 foetal calf serum for flow cytometric analysis in a fluorescence activated cell sorting analyser using CELLQuest® software (Becton Dickinson, Heidelberg, Germany). Negative controls were performed with either no primary antibody or preimmune IgG fraction. For positive control a mouse anti-HLA-ABC monoclonal antibody (DAKO Diagnostica, Hamburg, Germany) was used.
Immunohistochemistry
The cells were washed three times in phosphate-buffered saline at 4 °C to remove traces of culture medium, then resuspended in phosphate-buffered saline at an approximate cell concentration of 2xl0 9 /l. The suspension (50-ΙΟΟμΙ) was pipetted onto a premarked area of silanized glass slides and allowed to settle for 10 ! ) Enzymes: Factor VII (EC 3.4.21.2) Factor X (EC 3.4.21.6) Peroxidase from horseradish (EC 1.11.1.7)
2 ) Abbreviations cDNA, copy deoxyribonucleic acid DNA, deoxyribonucleic acid dNTP, 2'-deoxynucleoside 5'-triphosphate PCR, polymerase chain reaction RNA, ribonucleic acid min. Residual suspension was removed by tapping and the cells were air dried for a further 10 min. The slides were then fixed in 30 g/1 paraformaldehyde in phosphate-buffered saline for l h and washed in distilled water. The slides were passed through graded aqueous solutions of absolute ethanol then air dried at 4 °C. Prior to staining the preparations were rehydrated in phosphate buffered saline.
Tissue factor pathway inhibitor activity assay
The inhibitory activity of tissue factor pathway inhibitor in cell culture supernatant was measured by a modified chromogenic substrate assay based on the ability to inhibit factor X 1} activation by factor Vila/tissue factor 1 ) complex. Tissue factor (25 μΐ, dilution 1:80, Baxter, Unterschlei heim, Germany) and 25 μΐ factor VII (0.0125 U) were added to 25 μΐ 0.075 mol/1 CaCl 2 and 25 μΐ factor X (0.025 U) and incubated for 15 min at 37 °C with vigorously shaking. Heat-inactivated sample (25 μΐ, dilution up to 1:20) was added, followed by incubation again for 15 min at 37 °C with vigorous shaking. A further 25 μΐ factor X (0.4 U) were then added immediately, and the incubation continued for 10 min at 37 °C. The chromogenic reaction was then started by adding 25 μΐ synthetic substrate (2.7 mol/1 N-benzoyl-Ile-GluGly-Arg-p-nitroanilide, Chromogenix, Essen, Germany). The absorbance was measured at 405 run after 30 min. The clotting factors and samples were diluted in assay buffer containing 0.05 mol/1 Tris/HCl, 0.1 mol/1 NaCl and 10 g/1 human albumin (Armour Pharma, Eschwege, Germany), pH 8.O. For quantification the test sytem was calibrated with truncated recombinant tissue factor pathway inhibitor (19) .
Results
Determination of antisera specificity
The antisera were used in a dot blot assay against each synthesized oligopeptide. Staining with a secondary anti-rabbit horse radish peroxidase monoclonal antibody was only observed with the corresponding antigen. Thus, we found no cross-reactivity with either of the other domain-specific recognition sites (tab. 1). Furthermore, free plasma tissue factor pathway inhibitor was detected in a dot blot assay by all antisera (data not shown). This indicates the specificity of the immunglobulin fractions toward the complete tissue factor pathway inhibitor protein and demonstrates the presence of all tissue factor pathway inhibitor domains in the plasma.
Flow cytometric tissue factor pathway inhibitor detection with polyclonal IgG fractions
The purified IgG fractions of each antiserum were used to detect tissue factor pathway inhibitor on the cell surface. The titre was 1:100 with IgG stock solution prepared from 10 ml rabbit serum. All tissue factor pathway inhibitor single domains were detected by the corresponding antiserum on the surface of endothelial cells (human umbilical vein endothelial cells) and endothelial cell lines (EA.hy 926, ECV304) by flow cytometry ( fig.  1 ). Since tissue factor pathway inhibitor was not detected in the supernatant after trypsin/ethylenediaminetetraacetic acid treatment (data not shown) it is concluded that this treatment did not release the membranebound inhibitor. The fluorescence intensity in the fluorescein isothiocyanate channel (FL1) was approximately 50% (10 2 events) compared with the density of HLA-ABC antigens (10 3 events). The overall tissue factor pathway inhibitor expression on endothelial cells and two endothelial cell lines was significantly higher than that on other cell lines such as synovial cells (McCoy), synovial sarcoma (SW982), chondrosarcoma cells (SW982) and leukaemic monocytes (THP-1) ( fig.  2 ). This is in accordance with the observation that endothelial cells are the main source of the inhibitor.
Immunostaining of fixed endothelial cells with the monospecific antisera
In immunohistochemical experiments we were also able to stain fixed endothelial cells with each of the three tissue factor pathway inhibitor-specific IgG fractions. The associated primary antibodies were detected with a secondary anti-rabbit horse radish peroxidase-coupled antibody. The optimal titres of IgG fractions were determined as 1:500.
Effect of heparin on the tissue factor pathway inhibitor presentation on the cell surface
To evaluate the tissue factor pathway inhibitor releasing effect of heparin, we analysed endothelial cells after heparin incubation by flow cytometry with our three polyclonal antibodies. To exclude fast tissue factor pathway inhibitor resynthesis and presentation, either the cellular protein synthesis or translocation were inhibited, using monensin or puromycin, respectively. In comparison with endothelial cells incubated without heparin, the tissue factor pathway inhibitor density on the surface of cells incubated after addition of low-molecular-weight heparin was only slightly decreased ( fig. 3) . Similar results were obtained in the presence and absence of monensin or puromycin.
Measurement of tissue factor pathway inhibitor concentration in the culture medium
The tissue factor pathway inhibitor concentration was measured in the cell culture medium (10 5 cells per well) of endothelial cells after addition of 10000 U/l heparin and without heparin over a period of 48 hours by a chromogenic substrate assay. Our results clearly demonstrate a heparin-mediated tissue factor pathway inhibitor release from endothelial cells into the extracellular space ( fig. 4) . Incubation with heparin (10000 U/l) results in a 2-4 fold increased tissue factor pathway inhibitor concentration (140-280 μg/l) compared with cells cultivated without heparin (80-130 μg/l).
Detection of tissue factor pathway inhibitor-specific mRNA In addition to endothelial cells and endothelial cell lines ECV304/EA.hy 926, tissue factor pathway inhibitorspecific DNA transcription products were also detected in chondrosarcoma (SW1353), synovial sarcoma (SW982), synovial cells (McCoy) and leukaemic monocytes (THP-1) by reverse transcription PCR. The cloned PCR-fragments were identified as the coding region of tissue factor pathway inhibitor domain 63 by DNA sequencing (data not shown).
Discussion
Tissue factor pathway inhibitor, which is mainly synthesized by endothelial cells, is a natural anticoagulant in the extrinsic pathway of blood coagulation (20) . The main activity of tissue factor pathway inhibitor is to downregulate the initial activation of coagulation resulting from exposure of tissue factor to the blood (21) (22) . This activity is increased after in vivo administration of low-molecular-mass heparin (23) .
Heparin and fractionated low-molecular-mass heparin (24) induce increased plasma levels of tissue factor pathway inhibitor in vivo after subcutaneous administration and in endothelial cell culture supernatant (12) (13) (14) . The increased inhibitor concentration appears to be mediated by the release of tissue factor pathway inhibitor from the endothelial cell surface where tissue factor pathway inhibitor is possibly present in association with proteoglycans (25), or from intracellular stores. Thus, tissue factor pathway inhibitor may function as an important regulator of thrombin formation on the vascular surface.
Our interest was focused on tissue factor pathway inhibitor presentation on the cell surface. Determination of the surface expression by flow cytometric methods was made possible by our new monospecific polyclonal antibodies ( fig. 5 ). These antibodies were obtained by immunization of rabbits with synthetic oligopeptides representing the reactive site of each Kunitz-type domain.
Each tissue factor pathway inhibitor single domain was detected by the corresponding antiserum on the surface of endothelial cells (human umbilical vein endothelial cells, ECV304, EA.hy 926), synovial cells, synovial sarcoma, chondrosarcoma and leukaemic monocytes. We also determined tissue factor pathway inhibitor-specific mRNA-transcripts in these cell lines to ensure that tissue factor pathway inhibitor gene transcription had occurred.
As the main source of vascular tissue factor pathway inhibitor, endothelial cells showed a higher surface expression of the inhibitor compared with other tested cell lines. According to the results of flow cytometry, heparin did not release surface bound tissue factor pathway inhibitor from endothelial cells. Even when protein synthesis and translocation were inhibited by monensin or puromycin, heparin did not alter significantly the tissue factor pathway inhibitor density on the endothelial cell surface. However, we found an increased tissue factor pathway inhibitor concentration in the extracellular space with our chromogenic substrate assay. This suggests that membrane-bound tissue factor pathway inhibitor is not the source of elevated inhibitor concentrations after heparin induction. Increased tissue factor pathway inhibitor levels, as measured in the cell culture supernatant after heparin incubation, might be derived from intracellular stores, as shown for von Willebrand factor, which is derived from Weibel-Palade bodies or secreted directly from the endothelial cytosol (26) .
The third domain 53 of tissue factor pathway inhibitor has been postulated as the binding site on the cell surface, where it mediates, in combination with the C-terminus, the association with other molecules, e. g. proteoglycans, lipoproteins and heparin (5, 27) . not influenced by heparin. We therefore suggest that the C-terminus, and not the third domain, is probably the tissue factor pathway inhibitor binding site. The releasing effect of heparin remains unclear even though strong evidence points to an intracellular mechanism.
